Treatment of non-small cell bronchogenic carcinoma with vinblastine and mitomycin: A southwest oncology group study

Forty-five patients with stage III M₁ non-small cell bronchogenic carcinoma were treated with vinblastine (1 mg/m² by iv bolus twice a day on 2 consecutive days) plus mitomycin (10 mg/m² on Day 1). This treatment was repeated at 3-week intervals for three courses. Consolidation therapy with doxorubicin and cisplatin at doses of 50 mg/m² each was administered to responders every 4 weeks for two courses, with subsequent vinblastine and mitomycin maintenance therapy every 6 weeks. Eleven partial remissions (24%) were achieved, with a median duration of remission of 16 weeks (range, 8-32) and a median survival of 19 weeks. No differences were seen in median duration or remission or survival by cell type or performance status.